Psych Capital Plc Logo

Psych Capital Plc

A life sciences firm developing psilocybin treatments for anorexia and mental health conditions.

PSY | IL

Overview

Corporate Details

ISIN(s):
GB00BL6CJQ54
LEI:
213800WXCQ1C6GPLHH68
Country:
United Kingdom
Address:
17 HANOVER SQUARE, W1S 1BN LONDON
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Shortwave Life Sciences Plc, formerly Psych Capital Plc, is a life sciences company focused on developing innovative treatments for mental health conditions. The company has transitioned from its prior role as an investment and media firm to a dedicated drug development entity following its acquisition of Short Wave Pharma. Its primary clinical program focuses on advancing psilocybin as a potential breakthrough therapy for anorexia nervosa, a condition with no FDA-approved medication. Rooted in the Israeli innovation ecosystem, Shortwave employs an IP-driven, capital-efficient strategy, utilizing strategic partnerships to optimize its drug discovery and development processes for eating disorders and other mental health indications.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-06 08:25
Regulatory News Service
Patent Application Publication
English 13.4 KB
2025-11-04 12:45
Pre-Annual General Meeting Information
AGM, Treasury Policy & Capital Reorganisation
English 44.0 KB
2025-10-31 16:25
Annual Report
ANNUAL REPORT AND ACCOUNTS TO 30 APRIL 2025
English 248.8 KB
2025-09-10 08:00
Board/Management Information
Direction, Director Changes and Medical Adviser
English 20.9 KB
2025-08-19 13:50
Major Shareholding Notification
Holding(s) in Company
English 56.0 KB
2025-08-04 12:00
Board/Management Information
Clarification on Strategic Advisor Appointment
English 6.0 KB
2025-07-29 08:00
Share Issue/Capital Change
£250k Fundraising, New Directors & Review
English 27.3 KB
2025-06-24 14:10
Major Shareholding Notification
AQSE Only - Holding(s) in Company
English 56.2 KB
2025-06-16 11:21
Major Shareholding Notification
Holding(s) in Company
English 56.2 KB
2025-01-31 17:52
Earnings Release
Interim Results to 31 October 2024
English 115.6 KB
2024-12-23 13:00
Share Issue/Capital Change
Pre-Crowdfunding re Groundbreaking Treatment
English 9.5 KB
2024-11-29 16:16
Declaration of Voting Results & Voting Rights Announcements
Total Voting Rights
English 7.2 KB
2024-11-27 15:12
Board/Management Information
Director Appointment and SPA Update
English 26.7 KB
2024-10-31 18:39
Annual Report
YEAR ENDED 30 APRIL 2024 AND DIRECTOR RESIGNATION
English 176.8 KB
2024-09-19 08:00
Regulatory News Service
Positive Pre-Clinical Result Drive to Human Trials
English 10.7 KB

Automate Your Workflow. Get a real-time feed of all Psych Capital Plc filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Psych Capital Plc

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Psych Capital Plc via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

CRESCENT BIOPHARMA, INC. Logo
A biotech company developing bispecific antibody therapies to treat solid tumors.
United States of America
CBIO
Crinetics Pharmaceuticals, Inc. Logo
Develops novel therapeutics for rare endocrine diseases and related tumors.
United States of America
CRNX
CRISPR Therapeutics AG Logo
Develops transformative CRISPR gene-based medicines for diseases like sickle cell.
United States of America
CRSP
Crossject Logo
Develops needle-free auto-injectors for rapid drug delivery in medical emergencies.
France
ALCJ
CTC BIO, INC. Logo
Develops pharmaceuticals and feed additives for human and animal health using fermentation tech.
South Korea
060590
Cue Biopharma, Inc. Logo
Develops injectable biologics to selectively activate T cells for oncology & autoimmune disease.
United States of America
CUE
Cullinan Therapeutics, Inc. Logo
Developing differentiated immune-modulating therapies for cancer and autoimmune diseases.
United States of America
CGEM
CUMBERLAND PHARMACEUTICALS INC Logo
Acquires and commercializes branded medicines for acute care, gastroenterology, and oncology.
United States of America
CPIX
Cuorips Inc. Logo
Develops iPS cell therapies, like a cardiomyocyte sheet for severe heart failure.
Japan
4894
Cuprina Holdings (Cayman) LTD Logo
Biomedical firm specializing in Maggot Debridement Therapy for wound care in Singapore & Hong Kong.
United States of America
CUPR

Talk to a Data Expert

Have a question? We'll get back to you promptly.